{"transactions":[{"id":1051,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-02T21:28:35.000Z","date":"2026-08-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":737,"price":241.3899,"value":177904.3563,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":2389,"source":{"system":"sec-edgar","filing":"0001188919-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000118891926000015/edgardoc.xml","form_type":"4"}},{"id":1050,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-02T21:28:35.000Z","date":"2026-08-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":6,"price":244.0633,"value":1464.3798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":3126,"source":{"system":"sec-edgar","filing":"0001188919-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000118891926000015/edgardoc.xml","form_type":"4"}},{"id":692947,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-07T21:55:11.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":1605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027."}],"balance_after":3132,"source":{"system":"sec-edgar","filing":"0001188919-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000118891926000012/edgardoc.xml","form_type":"4"}},{"id":731812,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-06-18T21:00:21.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":39453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":39453,"derivative":{"exercise_price":15,"expiration_date":"2036-06-16","underlying":"Ordinary Shares","underlying_shares":39453},"source":{"system":"sec-edgar","filing":"0001188919-26-000010","document":"form4-06182026_050611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000118891926000010/form4-06182026_050611.xml","form_type":"4"}},{"id":746327,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:27:04.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":58393,"source":{"system":"sec-edgar","filing":"0001188919-26-000008","document":"wk-form4_1780950421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000118891926000008/wk-form4_1780950421.xml","form_type":"4"}},{"id":310131,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2026-05-04T20:28:34.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":4884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026."}],"balance_after":4884,"derivative":{"exercise_price":130.84,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":4884},"source":{"system":"sec-edgar","filing":"0001188919-26-000004","document":"wk-form4_1777926511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000118891926000004/wk-form4_1777926511.xml","form_type":"4"}},{"id":310130,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:28:34.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":1146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 1,146 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026."}],"balance_after":5484,"source":{"system":"sec-edgar","filing":"0001188919-26-000004","document":"wk-form4_1777926511.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000118891926000004/wk-form4_1777926511.xml","form_type":"4"}},{"id":873787,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-02T22:09:56.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":1527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026."}],"balance_after":1527,"source":{"system":"sec-edgar","filing":"0001188919-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000118891926000002/edgardoc.xml","form_type":"4"}},{"id":1101602,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-06-25T21:45:13.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":51804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":51804,"derivative":{"exercise_price":7.37,"expiration_date":"2035-06-22","underlying":"Ordinary Shares","underlying_shares":51804},"source":{"system":"sec-edgar","filing":"0001415889-25-018217","document":"form4-06252025_050609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000141588925018217/form4-06252025_050609.xml","form_type":"4"}},{"id":1149295,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-05-14T21:11:13.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":7614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":53848,"source":{"system":"sec-edgar","filing":"0001802768-25-000055","document":"wk-form4_1747257065.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000055/wk-form4_1747257065.xml","form_type":"4"}},{"id":322399,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2025-05-08T22:22:50.000Z","date":"2025-05-07","kind":"grant","planned":false,"acquired":true,"shares":6809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025."}],"balance_after":6809,"derivative":{"exercise_price":98.9,"expiration_date":"2035-05-07","underlying":"Common Stock","underlying_shares":6809},"source":{"system":"sec-edgar","filing":"0001127602-25-013747","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760225013747/form4.xml","form_type":"4"}},{"id":322398,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-08T22:22:50.000Z","date":"2025-05-07","kind":"grant","planned":false,"acquired":true,"shares":1516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 1,516 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.  The RSUs vested immediately upon the grant date of May 7, 2025."}],"balance_after":4338,"source":{"system":"sec-edgar","filing":"0001127602-25-013747","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760225013747/form4.xml","form_type":"4"}},{"id":1468018,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-06-27T20:15:12.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":33595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over the 12 months following June 25, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":33595,"derivative":{"exercise_price":13.32,"expiration_date":"2034-06-24","underlying":"Ordinary Shares","underlying_shares":33595},"source":{"system":"sec-edgar","filing":"0001415889-24-018328","document":"form4-06272024_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000141588924018328/form4-06272024_040609.xml","form_type":"4"}},{"id":1485056,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-06-10T20:16:36.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":9293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":46234,"source":{"system":"sec-edgar","filing":"0001802768-24-000035","document":"wk-form4_1718050587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000035/wk-form4_1718050587.xml","form_type":"4"}},{"id":333983,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2024-05-09T21:30:52.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":12648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024."}],"balance_after":12648,"derivative":{"exercise_price":64.92,"expiration_date":"2034-05-08","underlying":"Common Stock","underlying_shares":12648},"source":{"system":"sec-edgar","filing":"0001127602-24-014818","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760224014818/form4.xml","form_type":"4"}},{"id":333982,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-09T21:30:52.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":2310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 2,310 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.  The RSUs vested immediately upon the grant date of May 8, 2024."}],"balance_after":2822,"source":{"system":"sec-edgar","filing":"0001127602-24-014818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760224014818/form4.xml","form_type":"4"}},{"id":341150,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2024-02-06T23:01:38.000Z","date":"2024-02-02","kind":"grant","planned":false,"acquired":true,"shares":2996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of February 2, 2024."}],"balance_after":2996,"derivative":{"exercise_price":76.96,"expiration_date":"2034-02-02","underlying":"Common Stock","underlying_shares":2996},"source":{"system":"sec-edgar","filing":"0001127602-24-003597","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760224003597/form4.xml","form_type":"4"}},{"id":341149,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-06T23:01:38.000Z","date":"2024-02-02","kind":"grant","planned":false,"acquired":true,"shares":512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 512 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.  The RSUs vested immediately upon the grant date of February 2, 2024."}],"balance_after":512,"source":{"system":"sec-edgar","filing":"0001127602-24-003597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760224003597/form4.xml","form_type":"4"}},{"id":1709936,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:39:32.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2044,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2044},"source":{"system":"sec-edgar","filing":"0000950170-23-070880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070880/ownership.xml","form_type":"4"}},{"id":1709935,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:39:32.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":449,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":449},"source":{"system":"sec-edgar","filing":"0000950170-23-070880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070880/ownership.xml","form_type":"4"}},{"id":1709934,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:39:32.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3676,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":135.63,"expiration_date":"2032-05-13","underlying":"Common stock","underlying_shares":3676},"source":{"system":"sec-edgar","filing":"0000950170-23-070880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070880/ownership.xml","form_type":"4"}},{"id":1709933,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:39:32.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":147.5,"expiration_date":"2031-05-14","underlying":"Common stock","underlying_shares":3462},"source":{"system":"sec-edgar","filing":"0000950170-23-070880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070880/ownership.xml","form_type":"4"}},{"id":1709932,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:39:32.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4460,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":161.82,"expiration_date":"2030-08-17","underlying":"Common stock","underlying_shares":4460},"source":{"system":"sec-edgar","filing":"0000950170-23-070880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070880/ownership.xml","form_type":"4"}},{"id":1709931,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T18:39:32.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4255,"price":229,"value":974395.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-070880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070880/ownership.xml","form_type":"4"}},{"id":1814775,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-08-04T21:34:57.000Z","date":"2023-08-03","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of August 3, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":10.57,"expiration_date":"2033-08-02","underlying":"Ordinary Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-044640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000120919123044640/doc4.xml","form_type":"4"}},{"id":1844288,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-06-26T20:11:20.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":36941,"source":{"system":"sec-edgar","filing":"0001209191-23-039689","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123039689/doc4.xml","form_type":"4"}},{"id":1870678,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T18:22:08.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":2044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units and will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest in full on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":6748,"source":{"system":"sec-edgar","filing":"0001203311-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000062/edgardoc.xml","form_type":"4"}},{"id":2141140,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":118090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":29.87,"underlying":"Common Stock","underlying_shares":118090},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141139,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":132433,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":44.48,"underlying":"Common Stock","underlying_shares":132433},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141138,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":114190,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":65.82,"underlying":"Common Stock","underlying_shares":114190},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141137,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":48.44,"underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141136,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":122000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":59.6,"underlying":"Common Stock","underlying_shares":122000},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141135,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":114515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":16.4,"underlying":"Common Stock","underlying_shares":114515},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141134,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":141400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":141400},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141133,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":109116,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":109116},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141132,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":63768,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":63768},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141131,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":47223,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47223},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141130,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":26865,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26865},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141129,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141128,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":false,"nature":"By Daughter"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141127,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":false,"nature":"By Daughter"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141126,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":102000,"ownership":{"direct":false,"nature":"By Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141125,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":119650,"ownership":{"direct":false,"nature":"By Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141124,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":119650,"ownership":{"direct":false,"nature":"By Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2141123,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:38.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":576318,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322033149/doc4.xml","form_type":"4"}},{"id":2149348,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-30T00:45:13.000Z","date":"2022-09-27","kind":"exercise","acquired":false,"shares":18291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying the option vested in equal quarterly installments over 16 quarters from January 17, 2017 through January 17, 2021."}],"balance_after":114515,"derivative":{"exercise_price":16.4,"expiration_date":"2027-01-16","underlying":"Common Stock","underlying_shares":18291},"source":{"system":"sec-edgar","filing":"0000899243-22-032261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322032261/doc4.xml","form_type":"4"}},{"id":2149347,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-30T00:45:13.000Z","date":"2022-09-27","kind":"exercise","acquired":true,"shares":18291,"price":16.4,"value":299972.4,"ownership":{"direct":true},"balance_after":576318,"source":{"system":"sec-edgar","filing":"0000899243-22-032261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322032261/doc4.xml","form_type":"4"}},{"id":2149346,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-30T00:45:13.000Z","date":"2022-09-13","kind":"gift","acquired":true,"shares":17650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust 2"},"balance_after":119650,"source":{"system":"sec-edgar","filing":"0000899243-22-032261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322032261/doc4.xml","form_type":"4"}},{"id":2149345,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-30T00:45:13.000Z","date":"2022-09-13","kind":"gift","acquired":true,"shares":17650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust 1"},"balance_after":119650,"source":{"system":"sec-edgar","filing":"0000899243-22-032261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322032261/doc4.xml","form_type":"4"}},{"id":2149344,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-30T00:45:13.000Z","date":"2022-09-13","kind":"gift","acquired":false,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":558027,"source":{"system":"sec-edgar","filing":"0000899243-22-032261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322032261/doc4.xml","form_type":"4"}},{"id":2149343,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-30T00:45:13.000Z","date":"2022-09-09","kind":"gift","acquired":false,"shares":221200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":593327,"source":{"system":"sec-edgar","filing":"0000899243-22-032261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322032261/doc4.xml","form_type":"4"}},{"id":2165266,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T23:00:25.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":9109,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":63768,"derivative":{"underlying":"Common Stock","underlying_shares":9109},"source":{"system":"sec-edgar","filing":"0000899243-22-030476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322030476/doc4.xml","form_type":"4"}},{"id":2165265,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T23:00:25.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":9444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":47223,"derivative":{"underlying":"Common Stock","underlying_shares":9444},"source":{"system":"sec-edgar","filing":"0000899243-22-030476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322030476/doc4.xml","form_type":"4"}},{"id":2165264,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:25.000Z","date":"2022-09-01","kind":"tax_withholding","acquired":false,"shares":9200,"price":68.15,"value":626980.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 18,553 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":814527,"source":{"system":"sec-edgar","filing":"0000899243-22-030476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322030476/doc4.xml","form_type":"4"}},{"id":2165263,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:25.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":9109,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":823727,"source":{"system":"sec-edgar","filing":"0000899243-22-030476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322030476/doc4.xml","form_type":"4"}},{"id":2165262,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:25.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":9444,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":814618,"source":{"system":"sec-edgar","filing":"0000899243-22-030476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322030476/doc4.xml","form_type":"4"}},{"id":2195435,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-08-03T22:01:22.000Z","date":"2022-08-01","kind":"exercise","acquired":false,"shares":8955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":26865,"derivative":{"underlying":"Common Stock","underlying_shares":8955},"source":{"system":"sec-edgar","filing":"0000899243-22-027637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322027637/doc4.xml","form_type":"4"}},{"id":2195434,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-08-03T22:01:22.000Z","date":"2022-08-01","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000899243-22-027637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322027637/doc4.xml","form_type":"4"}},{"id":2195433,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-03T22:01:22.000Z","date":"2022-08-01","kind":"tax_withholding","acquired":false,"shares":10018,"price":32.4,"value":324583.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 20,205 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":805174,"source":{"system":"sec-edgar","filing":"0000899243-22-027637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322027637/doc4.xml","form_type":"4"}},{"id":2195432,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-03T22:01:22.000Z","date":"2022-08-01","kind":"exercise","acquired":true,"shares":20205,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":815192,"source":{"system":"sec-edgar","filing":"0000899243-22-027637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322027637/doc4.xml","form_type":"4"}},{"id":2222134,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-06-24T20:57:23.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":6328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":29194,"source":{"system":"sec-edgar","filing":"0000899243-22-024040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322024040/doc4.xml","form_type":"4"}},{"id":2268740,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-05-17T19:32:28.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":3676,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3676,"derivative":{"exercise_price":135.63,"exercise_date":"2023-05-13","expiration_date":"2032-05-13","underlying":"Common Stock","underlying_shares":3676},"source":{"system":"sec-edgar","filing":"0000899243-22-018464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322018464/doc4.xml","form_type":"4"}},{"id":2268739,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T19:32:28.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":1503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest in full on May 13, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":4704,"source":{"system":"sec-edgar","filing":"0000899243-22-018464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322018464/doc4.xml","form_type":"4"}},{"id":2353513,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2022-03-04T01:51:19.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":118090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":118090,"derivative":{"exercise_price":29.87,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":118090},"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2353512,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T01:51:19.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":72877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":72877,"derivative":{"underlying":"Common Stock","underlying_shares":72877},"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2353511,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T01:51:19.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":72877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":72877,"derivative":{"underlying":"Common Stock","underlying_shares":72877},"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2353510,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T01:51:19.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":9445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":56667,"derivative":{"underlying":"Common Stock","underlying_shares":9445},"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2353509,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-04T01:51:19.000Z","date":"2022-03-01","kind":"tax_withholding","acquired":false,"shares":4074,"price":29.87,"value":121690.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,445 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":794987,"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2353508,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-04T01:51:19.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":9445,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":799061,"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2353507,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-04T01:51:19.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":839,"price":25.37,"value":21285.43,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":789616,"source":{"system":"sec-edgar","filing":"0000899243-22-009236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322009236/doc4.xml","form_type":"4"}},{"id":2413246,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T22:47:58.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":8955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":35820,"derivative":{"underlying":"Common Stock","underlying_shares":8955},"source":{"system":"sec-edgar","filing":"0000899243-22-004637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322004637/doc4.xml","form_type":"4"}},{"id":2413245,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T22:47:58.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000899243-22-004637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322004637/doc4.xml","form_type":"4"}},{"id":2413244,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T22:47:58.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0000899243-22-004637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322004637/doc4.xml","form_type":"4"}},{"id":2413243,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-03T22:47:58.000Z","date":"2022-02-01","kind":"tax_withholding","acquired":false,"shares":10531,"price":29.33,"value":308874.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 29,955 shares of Common Stock underlying the Reporting Person's RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Corrected balance; see Form 4/A filed on January 6, 2022."}],"balance_after":788777,"source":{"system":"sec-edgar","filing":"0000899243-22-004637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322004637/doc4.xml","form_type":"4"}},{"id":2413242,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-03T22:47:58.000Z","date":"2022-02-01","kind":"exercise","acquired":true,"shares":29955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Corrected balance; see Form 4/A filed on January 6, 2022."}],"balance_after":799308,"source":{"system":"sec-edgar","filing":"0000899243-22-004637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322004637/doc4.xml","form_type":"4"}},{"id":2441167,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-06T23:57:00.000Z","date":"2016-07-01","kind":"disposition_to_issuer","acquired":false,"shares":24821,"price":3.4,"value":84391.4,"ownership":{"direct":true},"balance_after":1117815,"source":{"system":"sec-edgar","filing":"0000899243-22-001260","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924322001260/doc4a.xml","form_type":"4/A","original_submission_date":"2016-12-16"}},{"id":2559722,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T23:00:15.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":8955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":44775,"derivative":{"underlying":"Common Stock","underlying_shares":8955},"source":{"system":"sec-edgar","filing":"0000899243-21-037666","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321037666/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559721,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T23:00:15.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":33750,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000899243-21-037666","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321037666/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559720,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T23:00:15.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."}],"balance_after":9750,"derivative":{"underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0000899243-21-037666","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321037666/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559719,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-24T23:00:15.000Z","date":"2021-08-01","kind":"tax_withholding","acquired":false,"shares":14853,"price":27.33,"value":405932.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 29,955 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":789413,"source":{"system":"sec-edgar","filing":"0000899243-21-037666","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321037666/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559718,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-24T23:00:15.000Z","date":"2021-08-01","kind":"exercise","acquired":true,"shares":29955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":804266,"source":{"system":"sec-edgar","filing":"0000899243-21-037666","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321037666/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2578844,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-09-04T00:00:36.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":9444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":66112,"derivative":{"underlying":"Common Stock","underlying_shares":9444},"source":{"system":"sec-edgar","filing":"0000899243-21-035219","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321035219/doc4.xml","form_type":"4"}},{"id":2578843,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-04T00:00:36.000Z","date":"2021-09-01","kind":"tax_withholding","acquired":false,"shares":4683,"price":29.85,"value":139787.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,444 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":794174,"source":{"system":"sec-edgar","filing":"0000899243-21-035219","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321035219/doc4.xml","form_type":"4"}},{"id":2578842,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-04T00:00:36.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":9444,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":798857,"source":{"system":"sec-edgar","filing":"0000899243-21-035219","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321035219/doc4.xml","form_type":"4"}},{"id":2617225,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T23:07:22.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":8955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":44775,"derivative":{"underlying":"Common Stock","underlying_shares":8955},"source":{"system":"sec-edgar","filing":"0000899243-21-031381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321031381/doc4.xml","form_type":"4"}},{"id":2617224,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T23:07:22.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":33750,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000899243-21-031381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321031381/doc4.xml","form_type":"4"}},{"id":2617223,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T23:07:22.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."}],"balance_after":9750,"derivative":{"underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0000899243-21-031381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321031381/doc4.xml","form_type":"4"}},{"id":2617222,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-03T23:07:22.000Z","date":"2021-08-01","kind":"tax_withholding","acquired":false,"shares":14853,"price":27.33,"value":405932.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 29,955 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":789413,"source":{"system":"sec-edgar","filing":"0000899243-21-031381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321031381/doc4.xml","form_type":"4"}},{"id":2617221,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-03T23:07:22.000Z","date":"2021-08-01","kind":"exercise","acquired":true,"shares":29955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":804266,"source":{"system":"sec-edgar","filing":"0000899243-21-031381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321031381/doc4.xml","form_type":"4"}},{"id":2651973,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2021-06-30T00:43:54.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":5726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects an adjustment to the number of Class A Ordinary Shares beneficially owned by the reporting person based on the actual number of shares delivered to the reporting person upon the settlement of an award of restricted stock units granted to the reporting person as reported on August 13, 2020."}],"balance_after":22866,"source":{"system":"sec-edgar","filing":"0000950103-21-009695","document":"dp153556_4-love.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321009695/dp153556_4-love.xml","form_type":"4"}},{"id":2708751,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-05-18T19:28:40.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3462,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3462,"derivative":{"exercise_price":147.5,"exercise_date":"2022-05-14","expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":3462},"source":{"system":"sec-edgar","filing":"0001203311-21-000033","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331121000033/edgardoc.xml","form_type":"4"}},{"id":2708750,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T19:28:40.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":1402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"These restricted stock units shall vest in full on May 14, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":3201,"source":{"system":"sec-edgar","filing":"0001203311-21-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331121000033/edgardoc.xml","form_type":"4"}},{"id":2812260,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-03-04T00:38:40.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":75556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":75556,"derivative":{"underlying":"Common Stock","underlying_shares":75556},"source":{"system":"sec-edgar","filing":"0000899243-21-009548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321009548/doc4.xml","form_type":"4"}},{"id":2812259,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T00:38:40.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":132433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":132433,"derivative":{"exercise_price":44.48,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":132433},"source":{"system":"sec-edgar","filing":"0000899243-21-009548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321009548/doc4.xml","form_type":"4"}},{"id":2812258,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-04T00:38:40.000Z","date":"2021-02-28","kind":"grant","acquired":true,"shares":370,"price":36.21,"value":13397.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":774311,"source":{"system":"sec-edgar","filing":"0000899243-21-009548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321009548/doc4.xml","form_type":"4"}},{"id":2881185,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:41:20.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":8955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":53730,"derivative":{"underlying":"Common Stock","underlying_shares":8955},"source":{"system":"sec-edgar","filing":"0000899243-21-004779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321004779/doc4.xml","form_type":"4"}},{"id":2881184,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:41:20.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":45000,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000899243-21-004779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321004779/doc4.xml","form_type":"4"}},{"id":2881183,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:41:20.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":19500,"derivative":{"underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0000899243-21-004779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321004779/doc4.xml","form_type":"4"}},{"id":2881182,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:41:20.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":12063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12063},"source":{"system":"sec-edgar","filing":"0000899243-21-004779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321004779/doc4.xml","form_type":"4"}},{"id":2881181,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-04T00:41:20.000Z","date":"2021-02-01","kind":"tax_withholding","acquired":false,"shares":17893,"price":49.49,"value":885524.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 42,018 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":773941,"source":{"system":"sec-edgar","filing":"0000899243-21-004779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188919/000089924321004779/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-04T00:41:20.000000Z,2881181"}